Every story in this section, newest first — page 71 of 373.
Oil prices increased on Tuesday as renewed fighting between the United States and Iran raised concerns about potential supply disruptions from the Middle East, a major crude-producing region.
Li Auto (NASDAQ:LI) reported August 2026 deliveries of 37,679 vehicles, bringing the company’s cumulative deliveries to 1,801,834 vehicles as of August 31, 2026.
NIO (NYSE:NIO) reported August 2026 deliveries of 35,836 vehicles, up 14.5% year over year, including deliveries from its NIO, ONVO, and FIREFLY vehicle brands.
XPENG (NYSE:XPEV) reported August 2026 vehicle deliveries of 39,107 units, representing a 4% increase compared with the same period last year.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo received European Union approval for Enhertu (trastuzumab deruxtecan) combined with pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.
Elbit Systems (NASDAQ:ESLT) signed contracts totaling approximately $270 million with an international customer to supply advanced intelligence, surveillance, reconnaissance, and targeting systems over a period of up to six years.
Sasol (NYSE:SSL) reported audited financial results for the year ended June 30, 2026, with turnover rising 9% to R272.1 billion and adjusted EBITDA increasing 17% to approximately R61 billion.
S&P Global (NYSE:SPGI) completed its acquisition of datacenterHawk, adding proprietary intelligence on global data center, fiber optic, and related infrastructure markets to S&P Global Energy.
Australia's financial crimes regulator launched an investigation into Western Union Financial Services and parent entity Western Union (NYSE:WU).
Pyxis Tankers (NASDAQ:PXS) reported second quarter 2026 revenue of $12.1 million, up 32.6% year over year, with net income attributable to common shareholders of $2.8 million compared with a $2 million loss in the prior-year period.
Utah Medical Products (NASDAQ:UTMD) announced that its Femcare subsidiary acquired all common shares of UK-based Orion Medical Supplies for £3.6 million paid from company cash reserves.
Nvidia (NASDAQ:NVDA) announced a $3.5 billion investment in MediaTek through convertible bonds, expanding a partnership focused on AI data centers, consumer computing, and automotive platforms.
Helix Energy Solutions (NYSE:HLX) announced that shareholders approved the proposals required to complete its previously announced all-stock combination with Hornbeck Offshore Services.
Cadrenal Therapeutics (NASDAQ:CVKD) reported a positive outcome from a July 28, 2026 FDA Type D meeting regarding the planned Phase 3 registration study of CAD-1005 for heparin-induced thrombocytopenia.
American Financial Group (NYSE:AFG) completed the previously announced sale of Charleston Harbor Resort & Marina and expects to recognize approximately $125 million in pretax core operating earnings from the transaction.
Ensysce Biosciences (NASDAQ:ENSC) announced completion of enrollment in Part 3 of the PF614-MPAR-102 clinical study, evaluating its MPAR overdose-protection technology for opioid medicines.
Gentex (NASDAQ:GNTX) announced that its Board of Directors declared a third-quarter 2026 cash dividend of $0.12 per share.
C1 Fund (NYSE:CFND) reported second quarter 2026 results with net asset value of $42.63 million, or $6.49 per share, and investments across 11 digital asset services and technology companies.
Mobix Labs (NASDAQ:MOBX) announced a definitive agreement to acquire Vision Aerial, a U.S.-based drone manufacturer focused on aerospace, defense, infrastructure, and other industrial markets.
Construction Partners (NASDAQ:ROAD) announced the acquisition of Asphalt Express Enterprises, a liquid asphalt supply and hauling business serving hot-mix asphalt producers in Oklahoma and northern Texas.
CollPlant (NASDAQ:CLGN) signed a definitive agreement to acquire LightSolver, an Israeli deep-tech company developing pure photonic computing technology centered on its Laser Processing Unit platform.
Axsome Therapeutics (NASDAQ:AXSM) announced that the first patient has been dosed in SUMMIT, a Phase 3 trial evaluating AXS-05 for smoking cessation in adult smokers.
Karyopharm Therapeutics (NASDAQ:KPTI) submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval for XPOVIO (selinexor) combined with ruxolitinib to treat patients with myelofibrosis.
Eli Lilly (NYSE:LLY) reported 52-week results from the Phase 3b TOGETHER-PsO and TOGETHER-PsA trials showing Taltz (ixekizumab) plus Zepbound (tirzepatide) improved outcomes compared with Taltz alone in adults with psoriasis or psoriatic arthritis and overweight or obesity.
